Tom Rönnlund has been appointed CEO of Probi. Mr. Rönnlund has more than 20 years of experience working in sales, marketing, and general management positions in the healthcare industry. Most recently he served as CEO for the Norwegian company Navamedic ASA. Mr. Rönnlund will join Sweden-based company at the start of 2019.
 
Mr. Rönnlundjoined Navamedic ASA in 2015 as CEO and led the transformation of the company through geographical expansion, new partnerships, and driving growth in higher margin product segments. Navamedic ASA is a stock-listed Norwegian pharmaceutical and medtech company, marketing products to patients, hospitals, and pharmacies.
 
Prior to joining Navamedic ASA, Mr. Rönnlund has held several positions in sales, marketing and general management at IQVIA (formerly IMS Health) and in international biopharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly. He holds a master’s degree in business administration and economics from Stockholm University.
 
“I’m confident that Tom Rönnlund, as new leader of the Probi team, who already did a great job until now, will be able to take Probi to the next level of innovation and profitable growth, by always keeping science as our main asset. I also take this opportunity to thank Ole Sogaard Andersen who did an excellent job during the interim period,” stated Chairman of the Board Jean-Yves Parisot. 
 
“I am very excited to join Probi, a research-driven company with scientifically proven products and a team passionate about helping people live healthier lives, an important focus for me personally. The company is in a great position to expand through organic and acquisition-driven growth in a dynamic and fast-paced global market,” said Mr. Rönnlund.